Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-01-07

Clinical Trial Update: Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluating a single dose of canakinumab for efficacy and safety in hospitalized patients with acute gout.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Canakinumab (canakinumab)

Snippet

Sponsor: Novartis | Conditions: Arthritis, Gouty | Phase 2 | Status: COMPLETED | Results posted: 2013-01-07